Table 2.
Correlations of ABCG2 polymorphisms with clinicopathological parameters in patients with breast carcinoma.
| Characteristic | ABCG2 G34A | ABCG2 C421A | ||||||
|---|---|---|---|---|---|---|---|---|
| GG Number(%) |
GA/AA Number (%) |
P †,‡ | Adjusted OR (95% CI)§ |
CC Number (%) |
CA/AA Number (%) |
P †,‡ | Adjusted OR (95% CI)§ |
|
| Age, yrs | ||||||||
| <50 | 268 (46.94) | 303 (53.06) | 0.760† | 1 (reference) | 272 (47.64) | 299 (52.36) | 0.086† | 1 (reference) |
| ≥50 | 286 (47.83) | 312 (52.17) | 0.445‡ | 1.155 (0.798–1.670) | 256 (42.81) | 342 (57.19) | 0.079‡ | 1.396 (0.963–2.023) |
| Menopausal status | ||||||||
| Premenopausal | 263 (45.90) | 310 (54.10) | 0.316† | 1 (reference) | 265 (46.25) | 308 (53.75) | 0.431† | 1 (reference) |
| Postmenopausal | 291 (48.83) | 305 (51.17) | 0.222‡ | 0.795 (0.549–1.149) | 263 (44.13) | 333 (55.87) | 0.376‡ | 0.845 (0.583–1.226) |
| First-degree family history of breast cancer | ||||||||
| No | 434 (46.8) | 493 (53.2) | 0.442† | 1 (reference) | 417 (45.0) | 51.0 (55.0) | 0.718† | 1 (reference) |
| Yes | 120 (49.6) | 122 (50.4) | 0.414‡ | 0.888 (0.669–1.180) | 112 (46.3) | 130 (53.7) | 0.713‡ | 0.948 (0.713–1.260) |
| Tumor size (cm) | ||||||||
| ≤2.0 | 197 (45.8) | 233 (54.2) | 0.410† | 1 (reference) | 192 (44.7) | 238 (55.3) | 0.753† | 1 (reference) |
| >2.0 | 357 (48.3) | 382 (51.7) | 0.443‡ | 0.911 (0.717–1.157) | 337 (45.6) | 402 (54.4) | 0.712‡ | 0.956 (0.752–1.215) |
| Histology | ||||||||
| IDC | 431 (46.1) | 503 (53.9) | 0.234† | 1 (reference) | 415 (44.4) | 519 (55.6) | 0.452† | 1 (reference) |
| ILC | 36 (52.9) | 32 (47.1) | 0.286‡ | 0.765 (0.467–1.253) | 31 (45.6) | 37 (54.4) | 0.831‡ | 0.948 (0.577–1.555) |
| Clinical stages | ||||||||
| I or II | 290 (43.3) | 380 (56.7) | 0.001 † | 1 (reference) | 291 (43.4) | 379 (56.6) | 0.148† | 1 (reference) |
| III or IV | 264 (52.9) | 235 (47.1) | 0.002 ‡ | 0.687 (0.543–0.868) | 238 (47.7) | 261 (52.3) | 0.149‡ | 0.842 (0.666–1.064) |
| Lymph node metastasis status | ||||||||
| Node-negative | 291 (46.0) | 341 (54.0) | 0.317† | 1 (reference) | 283 (44.8) | 349 (55.2) | 0.724† | 1 (reference) |
| Node-positive | 263 (49.0) | 274 (51.0) | 0.363‡ | 0.898 (0.711–1.133) | 246 (45.8) | 291 (54.2) | 0.593‡ | 0.938 (0.743–1.185) |
| ER status | ||||||||
| Negative | 172 (45.1) | 209 (54.9) | 0.466† | 1 (reference) | 150 (39.4) | 231 (60.6) | 0.013 † | 1 (reference) |
| Positive | 296 (47.5) | 327 (52.5) | 0.518‡ | 0.919 (0.710–1.188) | 295 (47.4) | 328 (52.6) | 0.020 ‡ | 0.735 (0.566–0.953) |
| PR status | ||||||||
| Negative | 190 (47.5) | 210 (52.5) | 0.699† | 1 (reference) | 155 (38.8) | 245 (61.2) | 0.003 † | 1 (reference) |
| Positive | 278 (46.3) | 323 (53.7) | 0.663‡ | 1.058 (0.820–1.367) | 290 (48.3) | 311 (51.7) | 0.004 ‡ | 0.687 (0.530–0.8902) |
| HER2 status | ||||||||
| Negative | 233 (46.6) | 267 (53.4) | 0.945† | 1 (reference) | 222 (44.4) | 278 (55.6) | 0.828† | 1 (reference) |
| Positive | 228 (46.8) | 259 (53.2) | 0.944‡ | 0.991 (0.771–1.273) | 216 (44.4) | 271 (55.6) | 0.999‡ | 1.000 (0.777–1.286) |
| p53 status | ||||||||
| Negative | 158 (46.7) | 180 (53.3) | 0.828† | 1 (reference) | 142 (42.0) | 196 (58.0) | 0.155† | 1 (reference) |
| Positive | 235 (46.0) | 276 (54.0) | 0.835‡ | 1.030 (0.782–1.357) | 240 (47.0) | 271 (53.0) | 0.147‡ | 0.814 (0.617–1.075) |
| BRCA1 status | ||||||||
| Negative | 65 (48.9) | 68 (51.1) | 0.645† | 1 (reference) | 55 (41.4) | 78 (58.6) | 0.626† | 1 (reference) |
| Positive | 280 (46.7) | 320 (53.3) | 0.648‡ | 1.092 (0.749–1.590) | 262 (43.7) | 338 (56.3) | 0.590‡ | 0.900 (0.614–1.319) |
| BRCA2 status | ||||||||
| Negative | 141 (49.5) | 144 (50.5) | 0.354† | 1 (reference) | 118 (41.4) | 167 (58.6) | 0.406† | 1 (reference) |
| Positive | 198 (45.9) | 233 (54.1) | 0.345‡ | 1.156 (0.856–1.560) | 192 (44.5) | 239 (55.5) | 0.443‡ | 0.888 (0.665–1.203) |
IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor; p53, tumor suppressor protein 53; BRCA1, breast carcinoma type 1 susceptibility protein; BRCA2, breast carcinoma type 2 susceptibility protein.
† P values were calculated from 2-sided chi-square tests or Fisher's exact test.
‡ P values were calculated by unconditional logistic regression adjusted for age and menopause state.
§Adjusted OR and 95% CI values were calculated by unconditional logistic regression adjusted for age and menopause status.